Physician profile
James W John
NPI 1588628549
$9,828.51
in general payments reported to CMS, 2019-2025
62 companies · $2,097 in 2025
The $2,097 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.87 · 2020: $332 · 2021: $1,087 · 2022: $1,565 · 2023: $2,114 · 2024: $2,538 · 2025: $2,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,749.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.34 | 2020-2025 | |
| Novo Nordisk INC | $850.78 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $604.34 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $510.56 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $502.23 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Daiichi Sankyo INC. | $481.36 | 2020-2024 | Injectafer |
| Pfizer INC. | $464.18 | 2022-2025 | |
| Glaxosmithkline, LLC. | $389.90 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.77 | 2020-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.14 | 2020-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $244.57 | 2020-2025 | Nexletol |
| Antares Pharma, INC. | $229.77 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Ironwood Pharmaceuticals, INC | $210.90 | 2020-2024 | Linzess |
| Bayer Healthcare Pharmaceuticals INC. | $205.94 | 2022-2025 | |
| Viiv Healthcare Company | $195.97 | 2023-2025 | Apretude |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.